Results 181 to 188 of about 4,580 (188)

FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides

Nucleic Acid Therapeutics, 2017
Annemieke Aartsma-Rus
exaly  

Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment

Therapeutic Advances in Neurological Disorders, 2019
Jens Dreyhaupt, Paul Lingor
exaly  

Nusinersen a spinalis izomatrophia kezelésében

Ideggyógyászati szemle, 2018
Gabriella Sinkó, Zsuzsanna Kiss, Bernadette Kalman   +2 more
openaire   +1 more source

Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen

International Journal of Molecular Sciences
Isidro Ferrer, Colomina Maria José, Andres-Benito P   +2 more
exaly  

Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study

Lancet Regional Health - Europe, The
Paul Lingor, Tim Hagenacker, Andreas Hermann   +2 more
exaly  

Nusinersen/Risdiplam

Reactions Weekly
openaire   +1 more source

Apixaban/nusinersen

Reactions Weekly
openaire   +1 more source

Short review on determination of nusinersen for spinal muscular atrophy treatment

Microchemical Journal
Sylwia Studzinska
exaly